CHRISTOPHER RHODES: Open Payments
NPI 1538875356 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,421 in 37 payments from 10 companies in 2025. Trend: 2023 $43 · 2024 $178 · 2025 $1,421
Food & beverage: $1,421
| Company | Payments | Amount |
|---|---|---|
| Indivior Inc. | 9 | $250 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $216 |
| Alkermes, Inc. | 4 | $174 |
| Gilead Sciences, Inc. | 2 | $156 |
| Otsuka America Pharmaceutical, Inc. | 9 | $153 |
| Madrigal Pharmaceuticals | 1 | $140 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $140 |
| GlaxoSmithKline, LLC. | 1 | $109 |
| Neurocrine BioSciences, Inc. | 2 | $66 |
| Merck Sharp & Dohme LLC | 1 | $17 |
Products named: REXULTI, SUBLOCADE, VIVITROL, REZDIFFRA, CAPLYTA, Epclusa, BLUJEPA, INGREZZA.
Industry payments across MA — which companies pay providers there.
